Sinary The present study compares the prognostic potential of tumour grade and DNA ploidy status in patients with advanced-stage prostatic cancer. Two outcome groups were selected on the basis of time to progression and survival after orchiectomy. A poor-outcome group consisted of 32 therapy-resistant patients who experienced disease progression during the first year after orchiectomy and subsequently death due to prostatic cancer during the following year. A good-outcome group consisted of 27 therapy-responsive patients who showed disease regression and no signs of progression during a 3 year follow-up. The 
Metastatic prostatic cancer is an aggressive and incurable disease. At the time of diagnosis, about 75% of the patients have either locally advanced or disseminated disease. The skeleton is the primary site of metastases in 85% of the patients who die of prostate cancer (Jacobs, 1983) . So far, androgen deprivation is the only palliative treatment that gives symptomatic relief and disease regression, which are achieved in about 70% of the patients with metastatic disease. Disease regression is, however, not permanent, and after a while the tumour cells escape the influence of androgen suppression. The mean progression-free interval is 12-18 months and the mean survival is 24-36 months after the initiation of hormonal therapy, depending on the tumour cells' sensitivity to endocrine manipulation (Ernst et al., 1991; Mahler and Denis, 1992) . Histopathological grade, serum tumour markers and performance status are the parameters most used to predict the outcome for the individual patient with metastatic disease. However, no presently available parameter can distinguish patients with a favourable response from those with poor response to androgen withdrawal.
The two common histological grading systems for prostate carcinomas are the Gleason (1977) system and the WHO classification system (Mostofi et al., 1980) . Both are subjective methods with large variations in inter-and intra-observer reproducibility (Mostofi, 1976; Swanholm et al., 1990; Gleason, 1992) .
More objective methods that can afford greater accuracy in assessing the relative risk of progression and death from cancer diseases have been sought. Ploidy analysis of solid tumours has revealed a high aneuploidy rate in poorly differentiated tumours, and survival appears to be adversely affected by increasing DNA index (Merkel and McGuire, 1990; Williams and Daly, 1990) . Ploidy has also been suggested to be an important prognostic factor (Lee et al., 1988; Peters et al., 1990; Miller et al., 1991; Zetteberg and Forsslund, 1991; Forsslund et al., 1992) . Increasing frequency of DNA aneuploidy has been demonstrated with advanced stage and loss of tumour differentiation (Frankfurt et al., 1985 (White et al., 1990; Adolfsson and Tribukait, 1991; Hedlund et al., 1991) .
The aims of the present study were to investigate both the prognostic value of the histological grade according to WHO and Gleason classification systems and the prognostic value of DNA ploidy in the presence of skeletal metastases. Additionally, a statistical evaluation of inter-and intra-observer reproducibility of the two grading systems was performed.
Patent and methods

Patients
The Scandinavian Prostatic Cancer Group Study no.2 (SPCG-2) investigated the concept of total androgen blockade for metastatic prostatic cancer. This study found no advantage in adding cyproterone acetate (CPA) 150 mg daily to orchiectomy compared with the standard treatment orchiectomy (J0rgensen et al., 1993) . The present investigation is based on two outcome groups of patients, selected from the SPCG-2 study according to their time to progression and time to cancer-related death. All patients had histologically confirmed prostatic carcinoma and skeletal metastases (M1) diagnosed by bone scans or radiographs. None four or more nuclei exceeded the 5c value without cells in the 8c area or if a prominent peak was identified between 2c and 4c ( Figures 3 and 4) . Histograms with one, two or three nuclei exceeding Sc were classified as euploid ( Figure 5 ) (Berner et al., 1993 After deparaffinisation with xylol, the tissues were rehydrated in graded ethanol, rinsed in phosphate-buffered saline (PBS, pH 7.4), and incubated with protease (Sigma no. 24) at 37C for 60 min. During this period a Pasteur pipette was used for mechanical disintegration. The protease activity was stopped by adding 4 ml of cold PBS, and thereafter the specimens were rinsed twice in 4 ml of PBS. The suspension was filtered through a 100 pim nylon filter and the cell density was calculated with a Burker chamber before centrifugation in a cytospin centrifuge (Hettich, Tuttlingen, Germany) on polylysine-coated slides at 1250 g. The isolated cells were post-fixed in 4% formalin for at least 12 h at room temperature.
A hydrolysis curve was made at O min intervals up to 180 min with 5 N hydrochloric acid at 22C, followed by 2 h staining with basic fuchsin. The plateau of the curve was found to be at 60 min. The slides were studied using a Zeiss Axiotron microscope using plan-Neofluar 40 x /0.75 with a 546 nm green filter. Images were digitised using a chargecoupled device (CCD) camera (Hamamatsu C3077) and transferred to the IBAS image processing unit (Kontron, Germany) at a final magnification of 1400 x and a resolution of 254 nm per pixel. The ploidy analysis consisted of semiautomatic measurements of approximately 350 nuclei per specimen including 25-50 lymphocytes (serving as internal quality control).
From each image, only intact, well-prepared nuclei were selected, and used to measure morphometric and densitometric features. The analyses were done by measuring integrated optical density (IOD) after shading correction of each input image which consisted of 512 x 512 x 8 bits. All images were selected at random. For each image, all complete, wellpreserved nuclei were measured.
The inter-and intra-observer reproducibility of the measurements were recorded in five randomly selected slides, and the histogram classification was well agreed upon within all five cases. The software used for measurements and analysis, was developed by us, using C-library from Kontron Bildanalyse, Munich, Germany.
Classification of DNA histograms A specimen was classified as diploid (2c) if only one peak [coefficient of variation (CV) 4-15%, mean 8%] was present to the right of the diploid control cells. The relative distance between the control cells and the defined diploid peak was found to be 1.6 ± 0.23 (Figure 1 ). This diploid peak (2c) was used for calculation of the ploidy of the other peaks and the CV. A specimen was considered to be in the tetraploid range when more than 10% of the analysed nuclei were found in the tetraploid region (2 x 2c ± 2 x CV) (Figure 2 The inter-and intra-observer agreement of histological grading obtained with WHO and Gleason classification system was calculated by K-statistics and the computer software program 'Agree' was used (Swanholm et al., 1989) . The K-coefficient reveals whether the reproducibility of a diagnostic test exceeds that obtained by chance alone (Landis and Kock, 1977; Silcocks, 1983) (Broders, 1926; Whitmore, 1973; Gleason et al., 1974; Mostofi, 1976) . As the treatment decision for any individual prostatic cancer patient is influenced by histological grade, the accuracy as well as the reproducibility of different grading systems are of utmost importance (ten Kate et al., 1986) .
The present study involved 59 patients chosen from the 273 patients in the SPCG-2 study (J0rgensen et al., 1993) . The SPCG-2 study was designed to include only well-differentiated and moderately differentiated tumours. Two experienced pathologists reviewed the histological slides from these 59 patients independently, and 27% and 37% of the tumours were graded as poorly differentiated. The (Mostofi, 1976; ten Kate et al., 1986; Gleason, 1992; Swanholm et al., 1992) al., 1985; De Voogt et al., 1989; Mulders et al., 1990; Ernst et al., 1991; Hedlund et al., 1991) . On the other hand, a similarly designed study (Miller et al., 1991) found that 76% of poorly differentiated tumours occurred in a bad outcome group and 65% of the well-differentiated tumours occurred in a good-outcome group in patients with metastatic disease.
Because of the possibility of using paraffin-embedded archival tumour material for DNA ploidy analysis, patient groups with known clinical outcome can be selected for studies of the prognostic value of ploidy. A review of 47 different DNA ploidy studies involving 3493 patients has indicated that in most studies DNA aneuploidy is positively correlated with high-grade tumours, advanced stage and, consequently, with short time to progression and death (Visakorpi et al., 1993) . Most of these studies were performed on localised or locally advanced-stage disease. Only a few studies on metastatic (Ml) disease have been reported. The present analysis of 59 cases did not demonstrate any signifint difference (P = 0.38) between the two outcome groups of patients with regard to diploid, tetraploid and aneuploid tumours. Our results concur with other ploidy investigations on metastatic prostatic cancer (White et al., 1990; Adolfsson and Tribukait, 1991; Hedlund et al., 1991 Some reports indicate that diploid and tetraploid tumours respond better to hormonal therapy than aneuploid tumours (Tavares et al., 1973; Zetteberg and Esposti, 1980; Zetteberg and Forsslund, 1991) . In these studies the endocrine treatment was initiated at earlier stages of the disease, where DNA ploidy has indicated important prognostic information for groups of patients. The present study confirms other reports (White et al., 1990; Adolfsson and Tribukait, 1991; Hedlund et al., 1991) that ploidy cannot predict the response to endocrine treatment in individual patients when distant metastases have already appeared.
When analysing tumour material from the prostate gland, heterogeneity within the tumour should be taken into account (Lange and Narayan, 1983 (Table III) was found in both patient groups.
To conclude, we could not find any significant differences between therapy-sensitive and therapy-resistant patients when using either histological grade or ploidy status evaluation. When distant metastases have appeared the prognostic importance of histological grade as well as DNA ploidy seems to be minor according to present results. Furthermore, histological grading is subjective and inaccurate. Future investigations should search for other prognostic factors that can predict more accurately the outcome in individual patients with metastatic prostatic cancer.
